We report modifications to immunocytochemical detection procedures for proliferating cell nuclear antigen (PCNA) which permit its identification in liver samples previously fued for BrdU immunocytochemistry. Both methods have been used for the assessment of phenobarbital-induced cell proliferation in rat liver. The difficulties associated with the hitherto unsuccessful application of PCNA immunocytochemical methods to tissues fued in formalin for BrdU visualization were overcome by epitope unmasking with acid hydrolysis, extension of primary antiserum (Pc10) incubation, and employment of streptavidin-ABC-HRP. BrdU delivery via osmotic minipumps for 48 hr before euthanasia, followed by fuation in cold formalin for 14 days, yielded reliable and reproducible hepatocellular labeling and a peak of cell proliferation in all lobes on Day 3 (i.e., labeling dur-
Introduction
Measurements of cell turnover and proliferation are employed in a wide variety of clinical and experimental investigations of cell and tissue kinetics (Eldridge et al., 1991; Dawson et al., 1990; Hanazono et al., 1990; McDowell et al., 1990; Schwartz et al., 1989; Kurki et al., 1986) . In clinical medicine, such studies performed in combination with other complementary assessments are now providing new and important information that enables finer separation in tumor diagnosis (Raghavan et al., 1990) . Determination of the steady-state or growth phase of tumors contributes an influential diagnostic detail to the design of appropriate therapeutic treatment (Coltrera and Gown, 1991; Kute and Quadri, 1991) .
During the safety evaluation of potential new drugs and chemicals, the determination of a compound's genotoxic, mutagenic, and carcinogenic potential is of fundamental importance Schulte-Hermann, 1985) . Most genotoxic carcinogens are detectable as mutagens in in vitro tests such as the Ames UK. ing Days 1-3) of dosing with 80 mglkglday phenobarbital.
Labeling indices (LI) of both control and phenobarbitaltreated liver were lower in the left and right median lobes as compared with the lateral lobes. In sections of the left lateral lobe from the same liver, PCNA immunocytochemistry reveated a peak of proliferative activity (about one third of the maximum LI generated by BrdU incorporation) on Day 1. These findings, together with the advantap and disadvantages of both techniques, are discussed in the context of their applications to Werent investigative requirements. (J Hisrochem Cytochem 41:21-27, 1993) Sdmone/la assay and sister chromatid exchange assay Gold, 1990,1992; Williams, 1980) . However, substances that are negative in these assays but generate tumors when administered chronically to rodents (the so-called non-genotoxic carcinogens) pose a significant problem for risk assessment (Buttetworth, 1991; Goldsworthy et al., 1990; McClain, 1990) . For commercial and scientific reasons and ethical concerns associated with limiting the use of laboratory animals, assessments of non-genotoxic carcinogenic potential are attracting the attention of pharmaceutical and chemical manufacturers and regulatory agencies alike. Increasingly, measurements of cell proliferation are being regarded as potentially valuable indicators of the early biological responses of target organs to non-genotoxic carcinogens (Bogdanffy et al., 1990) . A correlation has been established between carcinogenic potency and hepatocyte replication in rats exposed to peroxisome proliferators (Marsman et al., 1988) although, in general terms, the database currently available is inadequate for comparisons of the relationship between chemically induced cell proliferation and carcinogenic activity. Furthermore, Matthews and co-workers have demonstrated the value of cell proliferation evaluations in distinguishing between potent carcinogens and closely related structural isomers that display no carcinogenic activity .
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Assessment of cell proliferation both in vivo and in vitro has involved incorporation of [ 3H]-thymidine into cells during the DNA synthesis phase (S-phase) of the cell cycle, followed by autoradiography Loury et al., 1987) . This assessment can also be performed by use of bromodeoxyuridine (BrdU), a non-radioactive analogue of thymidine which is readily incorporated into cells during S-phase and evaluated by standard immunocytochemical methods (Frederiks et al., 1990; Hanazono et al., 1990; Lanier et al., 1989) . Owing to the requirement for invasive delivery procedures, use of BrdU or [3H]-thymidine, if uncontrolled, may affect the level of cell proliferation in the target tissue. Another useful marker of S-phase cells is an endogenous nuclear protein which is variably expressed at different phases of the cell cycle, the amount binding to chromatin increasing to a maximum at S-phase (Morris and Matthews, 1989) . Matthews et al. (1984) designated as proliferating cell nuclear antigen (PCNA) that protein which was identified as cyclin by Bravo et al. (1981) , the nuclear antigen restricted to proliferating cells and first described by Miyachi et al. (1978) .
The undoubted benefits of the use of BrdU in cell proliferation assessments, such as potential for long label exposures to summate the numbers of cells, either recruited into the proliferating cell population or those labeled in consecutive cycles, are bought at the expense of surgical intervention and the slight toxicity of this synthetic thymidine analogue. Employment of an endogenous marker of cell proliferation such as PCNA possesses advantages that circumvent physical and physiological stresses associated with osmotic pump implantation and toxicity, although labeling of only one cell cycle is achievable. Therefore, the major advantage of the use of PCNA immunocytochemical localization of replicating cells lies in the retrospective analysis of stored (archival) tissues (van Dierendonck et al., 1991; Waseem and Lane, 1990; Galand and Degraef, 1989) . Hitherto, comparisons of BrdU and PCNA immunocytochemical visualization of replicating or proliferating cells in tissue derived from the same formalin-fixed, paraffinembedded tissues have not been made. We have addressed this issue as part of a study of phenobarbital-induced cell proliferation in different rat tissues. The results pertaining to multitissue proliferative responses will be reported elsewhere; in this report we detail the new methodology involved in staining formalin-fiued rat liver tissue by either BrdU or PCNA immunocytochemistry.
Materials and Methods
Experimental Design
Twenty-eight Alderley Park Wistar rats aged 6-7 weeks and of 150 g minimum weight were housed in groups of four in suspended metal cages in a regulated environment (12-hr lightldark cycle; 45-7096 relative humidity) and given standard diet (SDS Modified Irradiated R&M No 1 (Special Diet Services; Manea, Cambridge, UK) and potable tapwater ad libitum. Twenty animals (five treatment groups of four animals each) received 80 mg sodium phenobarbital (Serva, Heidelberg, Germany)lkg (in sterile aqueous solution) by daily oral intubation for up to 7 days. Eight animals (two groups of four animals each, control groups) were given the vehicle only by the same route. Control and treatment groups were sacrificed by halothane (IC1 Pharmaceuticals; Macclesfield, UK) overdose at 0 and 8 days, and at 1, 2, 3, 5 , and 7 days, respectively. Each animal received BrdU for 48 hr via an Alzet osmotic minipump (Model number 2ML1, delivery 10 pllhr; Aha, Palo Alto, CA) before euthanasia. These were filled with sterile physiological saline containing 10 mglml of BrdU and implanted subcutaneously in the interscapular region.
At necropsy, the thoracic and abdominal cavities were examined for any macroscopically visible abnormalities and the liver was removed and weighed. Slices of the four major lobes (i.e., left and right laterals and medians) were immersed in ice-cold 10% neutral buffered formalin. These samples and the thyroids, pancreas, duodenum, ileum, kidneys, adrenals, pituitary, and testes (all whole or in slices) were immersed in cold fixative for 14 days at 2-6'C. After fiuation, the tissues were processed by conventional methods, embedded in paraffin, and 3-4-pm thick sections were cut, mounted on immunoadhesive-coated slides (Orthoadhesive; Ortho Diagnostics Systems, High Wycombe, UK), and dried in an oven (35'C) overnight before storage. The intetorgan comparison of cell proliferation stimulated by phenobarbital administration will be reported separately (Jones and Clarke, manuscript in preparation).
Immunocytochemistry
One objective of this comparison between BrdU and PCNA was to determine the preparative technique most suitable for assessment of cell proliferation in tissue sections. Several methods were evaluated and their relative advantages and disadvantages will be discussed. The criteria used for this evaluation were:
1. Positive staining of S-phase nuclei by immunocytochemistry and appropriate counterstaining of unlabeled nuclei on the same tissue section. 2. Consistency and reproducibility of immunostaining. 3. Possibility of transfer of immunostaining to autoimmunostainer. 4. Potential for use of image analysis for slide scoring.
BrdU
Pemxidase-Anu-peroxidase (PAP) Method. Tissue sections were d-ed in xylene and taken to water via graded alcohols. Trypsinization (0.1%) in 0.2 M Tris-HCI buffer (pH 7.8) for 10 min was followed by deionized water wash and then DNA hydrolysis with 1 M HCI at 56'C for 30 min. Endogenous peroxidase activity was blocked by immersion in 3% H z 0~ for 5 min and, after a further wash, normal rabbit serum (Dakopatts, Glostrup, Denmark; code x902, 1:20) was applied to the sections for 20 min. A PBS rinse for 5 min preceded incubation with primary antiserum (monoclonal mouse anti-human bromodeoxyuridine; DAKO BrdUrd, Code M744, 1:W) for 1 hr, followed by another 5-min PBS rinse before incubation for 20 min with secondary antiserum (rabbit anti-mouse immunoglobulins; Dakopatts, Code 2259, 1:50). A 5-min PBS rinse was followed by incubation with the tertiary layer antiserum (mouse peroxidase-anti-peroxidase; Dakopatts, Code P850, 1:50) for 5 min and then incubation with diaminobenzidine (DAB; 0.5 mglml) for 5 min. Sections were counterstained with Mayer's hematoxylin for 3 min.
Immunogold-Silver Staining (IGSS) Method. Sections were treated in the same way as previously described up to the DNA denaturation step, which was followed by washing in water and subsequently in PBS for 5 min. Incubation in normal goat serum (Dako, Santa Barbara, CA; 1:20) for 20 min and a 5-min PBS rinse preceded their incubation with primary antiserum (Dako BrdUrd; Code M744, 150). They were then washed in PBS for 5 min before immersion in Janssen (Beerse, Belgium) Auroprobe LM (Auroprobe LM goat anti-mouse IgG and IgM, 1:40)-labeled secondary antisera for 1 hr, followed by PBS wash for 5 min. Three washings in distilled water preceded incubation with Janssen Intense-M silver enhancement solution (equal parts Solutions A and B, mixed immediately before use) for 6-10 min. Sections were washed in running water and counterstained with Mayer's hematoxylin for 3 min.
PHENOBARBITAGINDUCED CELL PROLIFERATION
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PCNA
Peroxidase-Anti-peroxidase (PAP) Method. The experience of . using the PClO anti-cyclin monoclonal antibody, suggested that the duration of fixation was a critical determinant of the success of this technique. To assess the influence of fixation, liver was obtained from two untreated male control rats, housed and handled in the same way as detailed above. Slices of liver were fixed by immersion in 10% neutral buffered formalin at 2-6'C for either 24 or 48 hr. The tissues were embedded in paraffin as detailed above and sections of these samples and those fixed for 14 days were processed according to the following schedule.
Sections were dewaxed and taken to water through graded alcohols before blockade of endogenous peroxidase activity with 3% H202 for 5 min. After a brief aqueous wash, sections were immersed in normal rabbit serum (Dakopatts; Code X302,1:20) for 20 min. washed again, and incubated in primary antiserum [monoclonal mouse anti-human proliferating cell nuclear antigen (PCNA); Dako-PCNA, PC10, Code M879, 1:50] overnight. A brief (5-min) PBS rinse preceded incubation in the secondary antisera (rabbit anti-mouse immunoglobulins: Dakopatts, Code 2259, 1:50) for 20 min. followed by another brief(>-min) PBS rinse and incubation with the tertiary layer antiserum (monoclonal mouse peroxidase-anti-peroxidase; Dakopatts, Code P850, 1:50) for 20 min. Sections were then rinsed in PBS ( 5 min) and finally incubated with 0.5 mglml DAB for 5 min.
Avidin-Biotin-Peroxidase Complex (ABC) Method. Sections were processed in the same way as the previous PAP method for PCNA up to and including blockade of endogenous peroxidase activity. After a brief (5-min) PBS wash, sections were incubated in primary antiserum (Dako-PCNA; 1:50) for 72 hr and, after a rinse in PBS immersed in biotinylated goat anti-mouse antibodyhabbit immunoglobulins (Dako, Code K492,l:JO) for 30 min. A brief (5-min) PBS wash preceded incubation with streptavidin-ABC compledHRP (Dako, Code K492, 1:50) for 30 min, followed by a further PBS wash and incubation in 0.5 mg/ml DAB for 5 min.
Quantitative Assessment
All sections were examined at an objective lens magnification of x 25 with a Leitz Ergolux light microscope interfaced via a f l C ky-F30 camera to a Joyce Loebl Magiscan image analysis system (Applied Imaging; Gateshead, UK). Counts of immunopositive (brown) and hematoxylin-counterstained hepatocyte nuclei were made from 10 random fields per section from each lobe of BrdU-labeled liver. At least 1000 nuclei per tissue section were counted. Effective use of fully automated quantitative assessments was unobtainable due to miation ofperoxidase staining and hematoxylin-associated background staining. Attempts to eliminate background staining by the employment of selective nuclear stains, i.e., Feulgen, Kurnick's methyl green, methyl green pyronin. or gallocyanin chromalum, were successful when employed on non-immunoreacted sections but were unhelpful as counterstains on immunostained tissue owing to loss of immunopositivity. For the PC1O/ABC-immunostained sections, the optimal scoring procedure was to count positive (brown) hepatocyte nuclei in 10 random fields of a noncounterstained section. The total number of hepatocyte nuclei was assessed in 10 fields of a serial Feulgen-stained section, using fully automated image analysis.
The labeling index (LI) in BrdU-immunostained or PCNAimmunostained material, respectively, was calculated by using: 
Results
Immunocytochemistry
BdU. Both PAP and IGSS methods produced excellent immunostaining of hepatocellular nuclei and other nuclei when performed manually ( Figure 1A ). However, in our hands the latter method (which holds the potential advantage of its suitability for automated image analysis due to high-contrast labeled nuclei and low background) lacked the reproducibility of the former. Furthermore, the IGSS method produced variable staining and nonspecific background (silver deposition). The PAP method was transferable with confidence to the Cadenza automated immunostainer (Shandon Scientific; Runcom, UK) and was used for all subsequent immunostaining.
PCNA. In confirmation of the findings of , positive staining of hepatocellular and other nuclei was obtained in liver fixed for either 24 or 48 hr. Liver fixed for 14 days and processed by the PAP technique failed to demonstrate PCNApositive nuclei. Enhancement of PClO antibody binding by exposure of intranuclear cyclin (PCNA) was attempted by HCI hydrolysis for 30-60 min (Galand and Degraef, 1989 ) after dewaxing of tissue sections and modifying slightly the incubation conditions for the primary antiserum. Acid hydrolysis for 30 min and increasing primary antiserum incubation from 12-15 hr (overnight) to 7 2 hr resulted in the demonstration of positively stained nuclei in 75% of sections processed. Acid hydrolysis for more than 30 min resulted in failure of immunolabeling in the 14-day-fixed sample.
These inconsistencies prompted the utilization of the ABC method, which reliably produced high-quality material ( Figure 1B) . The modifications to the PCNA immunostaining procedure described above permitted BrdU and PCNA labeling in tissues fixed optimally for BrdU demonstration. We did not attempt colocalization of BrdU and PCNA in the same sections.
Quantitative Assessment
The liver weight/body weight ratio was elevated in phenobarbitaltreated rats by about 20% relative to controls on Day 7.
The objective of employing a fully automated image analysis assessment of tissue sections was not achieved in a resource-effective manner. Editing/deletion of automatically identified features was performed interactively with a light pen.
Interlobar Kiriation
Comparison of the labeling indices (LI) of liver immunostained by either the BrdU or the PCNA method demonstrated significant differences in both the magnitude and timing of hepatocellular proliferation.
In BrdU-immunostained tissue sections, differences in LI between different lobes of the liver were seen (Figure 2) . It was noteworthy that control LIS were, in general, level between Days 0 and 8 within any individual lobe, but their values differed significantly between median and lateral lobes. No differences were seen between the left and right sides of either median or lateral lobe. Phenobarbital administration resulted in maximal proliferation in all lobes on Day 3, left and right lateral lobes displaying a twofold increase by comparison with their median lobe counterparts (p<o.OOl). Moreover, both left median and lateral lobes showed a more rapid proliferative response than their counterparts on the right side ( Figure 2 ).
BraU vs PCNA LI ProfiZes
The LI profiie of the left lateral lobe, as defined by BrdU immunolabeling, was markedly different from that obtained from the same tissues by PCNA visualization. The LI peak seen after 1-3 days in the former preparations was present on Day 1 in PCNA immunostained tissue (compare Figures 2 and 3) . Both control and treated maximum LIS were about one third of the values seen in their BrdU-immunolabeled counterparts.
Discussion
We have detailed the demonstration of cell replicative profiles by BrdU and PCNA immunocytochemistry in the same h u e . This was achieved by the utilization of a monoclonal anti-PCNA antibody (PClo), incorporation of an HCI hydrolysis step, extending the duration of primary serum incubation, and employment of ABCIHRP visualization. Both methods yielded material with positively stained nuclei and minimal background staining, which permitted rapid and reproducible assessment of cell replicative rates. Eldridge et al. (1992b) have also demonstrated BrdU and PCNA labeling in serial sections of rat and mouse liver. 
PE-Treated
T Phenobarbital treatment resulted in a peak of cell proliferative activity on Day 3 (corresponding to a Day 1-3 labeling window) and a decline by Day 5 (3-5-day labeling window) in all lobes, as defined by BrdU labeling. On Day 7 (Day 5-7 labeling window) the LI had fallen a little below that of the control (Days 6-8) level, although this was not statistically significant. Control LIS (Days 0 and 8) were level and were approximately one third of those seen during phenobarbital administration. Although the timing of the peak of cell proliferation was the same in all lobes, the magnitude of the proliferative burst and its rate of change appeared to be lobe specific. Distinct and highly significant changes in peak height were observed between median and lateral lobes. It is noteworthy not only that the L.I peaks of the median lobes were about half those of the lateral lobes but that their corresponding basal replicative levels (controls) were lower by the same order. These data suggest that the degree of induction of cell proliferation may be the same throughout the liver but that the different underlying replicative activity of individual lobes may result in apparent interlobar differences in LIS. Interlobar differences in replicative activity and in diethyl nitrosamine (DEN)-induced hepatocellular carcinoma in male Fisher 344 rats have been described by Richardson et al. (1986) , who recorded 100% tumor incidence in the left and right median lobes and a 30% incidence in the right anterior lobe after 20 weeks of DEN exposure. These authors concluded that "interlobe differences in hepatocyte initiation and the incidence of hepatocellular carcinoma may be due in part to differences in cell replication and in DNA alkylation resulting from differential DEN distribution andlor metabolism." Moreover, Richardson et al. (1988) noted that hepatocellular initiation in DEN-exposed animals was dose and lobe related, i.e., left (left lateral) >right (right lateral) > right anterior (right median) lobes. Interlobar differences in LIS after phenobarbital administration to Alderley Park Wistar rats accords with this ranking. The interlobar differences in several functional paramete? are intriguing and represent clues to the multifocal activity of carcinogens. The LI profile in the left lateral lobe of the liver, as defined by PCNA visualization, differs from that demonstrated with BrdU immunostaining. Among control animals, the LI value obtained with PCNA was about one third of that seen with BrdU, although in relative terms the peak of cell proliferation due to phenobarbital administration was on the same order as that seen with BrdU. However, the peak of the proliferative burst appeared on the first day, 2 days before that seen in the same tissue after BrdU visualization. This difference can be reconciled by consideration of the basis for nuclear labeling. The PCNA is expressed during every cycle but is not retained between cycles, whereas BrdU is incorporated into each cell entering a division cycle and is retained Laskey et al., 1989) . BrdU incorporation and retention will continue as long as circulating BrdU levels are maintained, resulting in summation of labeled nuclei. PCNA labeling measures the LI of those cells in one division cycle only, whereas BrdU labeling over a fixed time period effectively measures the area under the cell kinetic curve, i.e., all cells that enter the division cycle during this time. Therefore, the LI peak is observed 24 hr after the start of dosing (PCNA result), while greater numbers of hepa-tocytes enter the division cycle during the Day 1-3 time period than during Days 0-2 (BrdU result). In our studies, use of a 48-hr BrdU infusion equated with incorporation over approximately three cycles (3 x 16 hr). That is, an increased number of cells were recruited into the labeled cell population during this time (rather than the same cell dividing three times). In this regard, it is interesting to note that the sum of the PCNA-derived LIS over the same period (Days 1-3 inclusive) is similar to that of the BrdU result (i.e., 6% and 6.5%, respectively). It might be argued that BrdU itself may induce hepatocellular proliferation. Eldridge et al. (1992a) report BrdU concentrations of up to 32 mg/ml delivered by minipump have no effect on observed rat liver LIS. The concentration used in the present study was 10 mg/ml. Quantitation of PCNA-and BrdU-based LIS in the rat liver has been performed by Eldridge et al. (in press) and Foley et al. (in press ). Eldridge and co-workers reported control PCNA LIS of 0.3% in rats, a value considerably lower than the values shown in Figure  3 . This is probably due to the difference in ages of the rats used (10 weeks for Eldridge et al. (in press) vs 6-7 weeks in our study) and serves to illustrate the care required in the design and interpretation of cell kinetics studies. The same authors have demonstrated compatibility between LIS measured by PCNA and BrdU delivered by a single IP injection. Such a direct comparison was not possible in the present study owing to the longer BrdU-labeling window. Goldsworthy et al. (1990) separate chemicals into two broad classes on the basis of several criteria, including the timing of the induction of cell proliferation. The first class includes those substances that are directly mitogenic and induce additive hyperplasia with little or no associated cytotoxicity. Administration of one of these substances to rodents generaies a peak of hepatocellular proliferation at about 24 hr. The second class of chemicals that induce cell proliferation are those which are cytotoxic and induce a regenerative response to compensate for cell death. After exposure to a single dose of such an agent, a peak of hepatocellular proliferation appears at about 48 hr. In this study, the peak of hepatocellular proliferation seen at 24 hr with PCNA immunocytochemistry, the absence of overt cytotoxicity, and the elevated liver weight/body weight ratio confirm the placement of phenobarbital into the first category of cell proliferators.
In conclusion, we have demonstrated the immunolabeling of PCNA-positive nuclei in liver tissue processed for optimal demonstration of cell proliferation by BrdU immunostaining. Both methods possess advantages and disadvantages and should be viewed as complementary to one another, each being best suited to certain investigations. The benefits of PCNA visualization relate to the avoidance of anesthesia, minipump implantation and infusion of BrdU, a mildly toxic substance [although Eldridge et al. (in press) have reported no effect of BrdU on hepatocyte replication rates at concentrations of 32 mg/ml or less when delivered by osmotic minipumps]. PCNA, yielding information of one cycle only, provides the opportunity to accurately define the temporal modulations in cell proliferation without surgical intervention. In contrast, BrdU infusion permits the assessment of low-level cell replication in a relatively small sample of the cell population by exploiting the summation of labeled nuclei that typifies this method.
